Dreyer L, et al. - Researchers, in this study, sought to determine the risk of a second malignant neoplasm (SMN) and mortality in patients with rheumatoid arthritis (RA) with a history of a primary cancer diagnosis and treated with biological disease-modifying antirheumatic drugs (bDMARD). They found that in this patient population, there was no relation of treatment with bDMARDs to increased risk of SMN. As regards to mortality in bDMARD-treated patients with RA, no clear conclusion could be drawn.